Toggle Main Menu Toggle Search

Open Access padlockePrints

Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation

Lookup NU author(s): Professor Mary Slatter, Professor Andrew GenneryORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2018 Background: Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity. Method: This study was an open-label phase 1/2 study to investigate the feasibility of generating donor-derived ADV-specific T cells (Cytovir ADV, Cell Medica) and to assess the safety of pre-emptive administration of ADV-specific T cells in high-risk pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) to treat adenoviremia. Primary safety endpoints included graft-versus-host disease (GvHD), and secondary endpoints determined antiviral responses and use of antiviral drugs. Results: Between January 2013 and May 2016, 92 donors were enrolled for the production of ADV T cells at three centers in the United Kingdom (UK), and 83 products were generated from 72 mobilized peripheral blood harvests and 20 steady-state whole blood donations. Eight children received Cytovir ADV T cells after standard therapy and all resolved ADV viremia between 15 and 127 days later. ADV-specific T cells were detectable using enzyme-linked immunospot assay (ELISpot) in the peripheral blood of all patients analyzed. Serious adverse events included Grade II GvHD, Astrovirus encephalitis and pancreatitis. Conclusion: The study demonstrates the safety and feasibility of pre-emptively manufacturing peptide pulsed ADV-specific cells for high-risk pediatric patients after transplantation and provides early evidence of clinical efficacy.

Publication metadata

Author(s): Ip W, Silva JMF, Gaspar H, Mitra A, Patel S, Rao K, Chiesa R, Amrolia P, Gilmour K, Ahsan G, Slatter M, Gennery AR, Wynn RF, Veys P, Qasim W

Publication type: Article

Publication status: Published

Journal: Cytotherapy

Year: 2018

Volume: 20

Issue: 6

Pages: 830-838

Print publication date: 01/06/2018

Online publication date: 09/05/2018

Acceptance date: 31/03/2018

ISSN (print): 1465-3249

ISSN (electronic): 1477-2566

Publisher: Elsevier BV


DOI: 10.1016/j.jcyt.2018.03.040


Altmetrics provided by Altmetric